Epilepsy clinical trials, in English

Objective: This protocol is designed to allow the Surgical Neurology Branch to evaluate and treat the neurosurgical disorders of protocol participants. The participants will receive standard-of-clinical-care evaluation and treatment.

NCT00060541 · Official ClinicalTrials.gov record · National Institute of Neurological Disorders and Stroke (NINDS)

Background: \- Drug resistant epilepsy is the term used to describe epilepsy that cannot be controlled by medication. Many people whose seizures do not respond to medication will respond to surgical treatment, relieving seizures completely or almost completely in one-half to two-thirds of patients who qualify for surgery.

NCT01273129 · Official ClinicalTrials.gov record · National Institute of Neurological Disorders and Stroke (NINDS)

The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research. Individuals affected by rare diseases, undiagnosed conditions, and disorders of unknown prevalence may voluntarily contribute health information to support natural history studies, participant recruitment, and other research efforts.

NCT01793168 · Official ClinicalTrials.gov record · Sanford Health

Background: \- The blood-brain barrier separates the brain from the rest of the body. Epilepsy is a neurological disease that causes seizures.

NCT02531880 · Official ClinicalTrials.gov record · National Institute of Neurological Disorders and Stroke (NINDS)

Background: Some people with brain tumors have seizures related to the tumor. Usually brain tumors are treated by removing as much of the brain tumor as possible without causing problems.

NCT02639325 · Official ClinicalTrials.gov record · National Institute of Neurological Disorders and Stroke (NINDS)

Epilepsy is a common condition which affects over 3 million people in the US. Patients with uncontrolled epilepsy have a lifetime risk of sudden unexpected death (SUDEP) of 35%, which is greatest in those under 40 years of age.

NCT02824822 · Official ClinicalTrials.gov record · Mayo Clinic

Background: Epilepsy affects about 1 percent of the U.S. Most people with epilepsy respond well to medicine, but some do not.

NCT03478852 · Official ClinicalTrials.gov record · National Institute of Neurological Disorders and Stroke (NINDS)

This is a multicenter, Phase 3, randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment study designed to measure the how well it works and safety of clemizole hydrochloride (EPX-100) as added on top of your current treatment therapy in children and adult participants with Dravet syndrome (DS).

NCT04462770 · Official ClinicalTrials.gov record · Epygenix

This clinical trial is designed to test whether a single image-guided intracerebral administration of inhibitory nerve cells, called interneurons (NRTX-1001), into subjects with drug-resistant unilateral mesial temporal lobe epilepsy (MTLE), with or without mesial temporal sclerosis (MTS), is safe (frequency of side effects) and effective (seizure frequency). NRTX-1001 comprises human interneurons that secrete a neurotransmitter, gamma-aminobutyric acid (GABA).

NCT05135091 · Official ClinicalTrials.gov record · Neurona Therapeutics

This is a Phase 3, multicenter, randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment study to measure the clinical how well it works, safety, and tolerability of XEN1101 administered as added on top of your current treatment treatment in primary generalized tonic-clonic seizures (PGTCS).

NCT05667142 · Official ClinicalTrials.gov record · Xenon Pharmaceuticals Inc.

The X-TOLE3 Phase 3 clinical trial is a randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment study that will measure the clinical how well it works, whether it is safe and how hard side effects are to live with of XEN1101 administered as added on top of your current treatment therapy in focal-onset seizures.

NCT05716100 · Official ClinicalTrials.gov record · Xenon Pharmaceuticals Inc.

Concurrent electroencephalography (EEG) and new tripolar EEG (tEEG) will be recorded from adult and pediatric patients. In some patients stereo EEG (sEEG) will also be recorded concurrently.

NCT05944692 · Official ClinicalTrials.gov record · CREmedical

This study wants to compare organization of normal brain function as detected using Functional magnetic resonance imaging (fMRI) in normal subjects as opposed to patients with epilepsy or brain tumors, to ascribe precise anatomic labels (including Brodmann Areas) and functional significance to each region involved in cognitive processes as detected by cortical stimulation mapping (CSM) in patients with implanted subdural electrodes (SDE) or depth (sEEG) electrodes, to describe the locations of these regions in Talairach space, for a population of patients without overt structural abnormalities in these regions, to generate a spatial probability map of locations of cortical regions "essential" for these processes, to compare the loci of "crucial" language, visual, motor and cognitive sites as determined by CSM with the loci determined by a battery of tasks using fMRI for each individual and to use these data in patients undergoing intracranial electro-corticographyto determine the loci of essential, involved and uninvolved brain areas, and use sophisticated mathematical analyses of these intracranial recordings to study information flow between these areas.

NCT05989893 · Official ClinicalTrials.gov record · The University of Texas Health Science Center, Houston

Vagus nerve stimulation (VNS) is an added on top of your current treatment treatment for refractory epilepsy. Although widely used, there is still a substantial number of patients with insufficient response.

NCT06304389 · Official ClinicalTrials.gov record · Cliniques universitaires Saint-Luc- Université Catholique de Louvain

A primary purpose of this study is to better understand what stimulation parameters work best for patients. For example, for Deep Brain Stimulation (DBS) of the Anterior Nucleus of the Thalamus (ANT), it is not clear what stimulation frequency leads is most effective.

NCT06617845 · Official ClinicalTrials.gov record · Mayo Clinic

This study aims to better understand how epilepsy alters brain function through neuroimaging of healthy people and people with epilepsy. The study investigates how changes in brain metabolism (sugar consumption, measured by positron emission tomography \[FDG-PET\], and blood flow, measured by functional magnetic resonance imaging \[fMRI\]) relate to abnormal interictal electrical activity associated with epilepsy (measured by electroencephalography \[EEG\]).

NCT06974305 · Official ClinicalTrials.gov record · Massachusetts General Hospital

The purpose of this research is to address the challenges of diagnosing and long-term management of epilepsy in participants whose seizures are not well captured by standard electroencephalography (EEG) tests and who cannot use or are not able to use more standard monitoring techniques. This research will compare the Minder System to standard of care in providing reliable seizure data.

NCT07110337 · Official ClinicalTrials.gov record · Epiminder America, Inc.

Identify and characterize electrocardiographic (ECG) changes occurring during the post-ictal phase of epileptic seizures. measure the duration and severity of post-ictal ECG abnormalities.

NCT07135713 · Official ClinicalTrials.gov record · Assiut University

The purpose of the research is to better understand how the human brain accomplishes the basic cognitive tasks of learning new information, recalling stored information, making decisions or choices about presented information and self-control. These investigations are critical to better understand human cognition and to design treatments for disorders of learning, memory, decision making and cognitive control.

NCT07350551 · Official ClinicalTrials.gov record · University of Texas Southwestern Medical Center

This self-crossover, randomly assigned controlled, pilot study aims to collect clinical data of bilateral stimulation of subthalamic nucleus (STN) combined with centromedian (CM) thalamus deep brain stimulation (DBS) for drug resistant epilepsy with motor symptom in adults.

NCT07458217 · Official ClinicalTrials.gov record · Boston Scientific Corporation

This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure frequency.

NCT07563881 · Official ClinicalTrials.gov record · Rapport Therapeutics Inc.

This is a phase I study (Protocol: UX-GIP001-102) investigating UX-GIP001 Injection, a novel cell therapy product consisting of human GABAergic interneuron progenitor cells (GIP), for treating adult patients with drug-resistant unilateral medial temporal lobe epilepsy (MTLE). The primary objective is to assess the safety, tolerability, and preliminary how well it works of UX-GIP001.

NCT07572812 · Official ClinicalTrials.gov record · Shanghai UniXell Biotechnology Co., Ltd

This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure frequency.

NCT07594119 · Official ClinicalTrials.gov record · Rapport Therapeutics Inc.

This study is being conducted to measure the safety and how well it works of JZP926 capsule in participants with Juvenile Myoclonic Epilepsy (JME).

NCT07723963 · Official ClinicalTrials.gov record · Jazz Pharmaceuticals

The goal of this clinical trial is to learn more about the home-based epilepsy self-management program, HOBSCOTCH, for improving cognitive function (thinking and memory) and quality of life specifically in young adults, ages 18 - 29 years, who have epilepsy. It will also learn if a modification of the program for youth with epilepsy, ages 13 - 17, improves thinking and memory and quality of life and reduces stress for their parents.

NCT07735715 · Official ClinicalTrials.gov record · Dartmouth-Hitchcock Medical Center

Perinatal stroke is a rare condition affecting approximately 20-40 births per 100,000. It may be ischemic or hemorrhagic and can occur before or around birth, with diagnosis sometimes delayed until motor or cognitive symptoms emerge.

NCT07898397 · Official ClinicalTrials.gov record · University Hospital, Strasbourg, France

People with epilepsy are predisposed to having seizures ("fits"), where abnormal electrical activity in the brain disrupts normal brain functioning. It is a common condition with around 1% of the population of Scotland having this condition.

NCT07903168 · Official ClinicalTrials.gov record · University of Aberdeen

Developmental and Epileptic Encephalopathies (DEEs) with a genetic cause represent a complex group of neurodevelopmental disorders characterized by intellectual disability and drug-resistant epilepsy. Because targeted, disease-modifying precision therapies like gene replacement and antisense oligonucleotides are rapidly approaching clinical trials, establishing objective diagnostic, prognostic, and therapeutic biomarkers is an urgent priority.

NCT07909382 · Official ClinicalTrials.gov record · Istituto Giannina Gaslini

A VNS longitudinal study focused on pre and post-VNS implantation in order to predict the VNS response and to understand better mechanisms of VNS using some connectivity and network measures.

NCT07909486 · Official ClinicalTrials.gov record · Cliniques universitaires Saint-Luc- Université Catholique de Louvain

This is a Phase 1, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment, 5-cohort study evaluating the pharmacokinetics (PK), safety, and tolerability of RAP-219-LAI in healthy participants aged 18 to 65 years. Assessment of up to four single-dose cohorts will characterize the PK profile of up to four ascending dose levels and evaluate dose proportionality.

NCT07923097 · Official ClinicalTrials.gov record · Rapport Therapeutics Inc.